Last reviewed · How we verify

Sumatriptan and Naproxen sodium

POZEN · FDA-approved active Small molecule

Sumatriptan activates serotonin 5-HT1B/1D receptors to relieve migraine pain, while naproxen sodium inhibits cyclooxygenase enzymes to reduce inflammation and provide additional analgesic effect.

Sumatriptan activates serotonin 5-HT1B/1D receptors to relieve migraine pain, while naproxen sodium inhibits cyclooxygenase enzymes to reduce inflammation and provide additional analgesic effect. Used for Acute migraine with or without aura.

At a glance

Generic nameSumatriptan and Naproxen sodium
SponsorPOZEN
Drug classTriptan/NSAID combination
Target5-HT1B/1D receptors (sumatriptan); COX-1/COX-2 (naproxen sodium)
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Sumatriptan is a selective serotonin receptor agonist that causes vasoconstriction of cranial blood vessels and inhibits neuropeptide release, addressing the vascular and neurogenic components of migraine. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that blocks COX-1 and COX-2 enzymes, reducing prostaglandin synthesis and providing complementary pain relief and anti-inflammatory effects. The combination targets migraine through multiple mechanisms for enhanced efficacy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: